Answers are grounded in this paper and cite their sources.
BACKGROUND: Bone marrow aspirate concentrate (BMAC) is a quick, minimally invasive, point-of-care therapy for equine orthopaedic injuries. Despite growing clinical use, standardised manufacturing methods are lacking, and the final product remains poorly characterised. OBJECTIVE: To develop a reproducible protocol for equine BMAC production that yields predictable cellular and cytokine compositions. STUDY DESIGN: In vitro analytical study. METHODS: Bone marrow aspirate (BMA) was harvested from the sternum of eight healthy adult horses and filtered to remove possible bony spicules. After centrifugation at 1000 × g for 10 min, the buffy coat was collected to generate BMAC. Cellular composition was assessed using standard haematology and cytology, and cytokine concentrations were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Data are presented as mean ± standard deviation. RESULTS: /μL. Anti-inflammatory cytokines were increased in BMAC: IL-1ra increased from 18,611.3 ± 5509.1 to 36,598.8 ± 5971.8 pg/mL; IL-10 from 9.0 ± 7.5 to 19.1 ± 15.6 ng/mL; and TGF-β1 from 2535.0 ± 3018.7 to 5073.8 ± 2175.9 pg/mL. Of the pro-inflammatory cytokines measured, only IL-1β was increased (287.5 ± 22.5 to 475.1 ± 206.0 pg/mL), while TNF-α and IL-6 were unchanged. MAIN LIMITATIONS: The small cohort size (n = 8) limited sensitivity for detecting minor effects. The cytokine panel, while representative, does not encompass all potential bioactive mediators, and single-time-point measurements do not necessarily reflect in vivo release kinetics. The clinical efficacy of BMAC was not evaluated, preventing direct correlation between compositional features and therapeutic outcomes. CONCLUSIONS: The BMAC protocol yielded consistently concentrated nucleated cells, preserved cellular morphology, and enhanced the anti-inflammatory cytokine profile relative to post-filtration BMA. These findings provide a biological rationale for intra-articular and intra-lesional use of BMAC in equine patients.
No takes yet. Share an insight, caveat, or question.
Branning et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: